Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

16.29
+0.24001.50%
Post-market: 16.25-0.0400-0.25%17:45 EDT
Volume:842.38K
Turnover:13.67M
Market Cap:2.17B
PE:7.07
High:16.46
Open:16.17
Low:15.93
Close:16.05
52wk High:19.25
52wk Low:10.34
Shares:133.05M
Float Shares:129.00M
Volume Ratio:1.09
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.07
ROE:66.12%
ROA:15.49%
PB:3.53
PE(LYR):7.87

Loading ...

Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain

Simply Wall St.
·
Aug 04

Aurinia Pharmaceuticals Inc Expected to Post Earnings of 24 Cents a Share - Earnings Preview

Reuters
·
Jul 27

New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)

Simply Wall St.
·
Jul 19

TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Jul 07

Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy

MT Newswires Live
·
Jul 06

Aurinia Pharmaceuticals announces initiation of PRESERVE study

TIPRANKS
·
Jul 06

Aurinia Pharmaceuticals Posts Corporate Presentation on Lupkynis Growth, Autoimmune Disease Pipeline Focus

Reuters
·
Jul 06

Aurinia Pharmaceuticals Announces Press Release Availability

Reuters
·
Jul 06

13D Filings -- Barrons.com

Dow Jones
·
Jun 13

Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook

Simply Wall St.
·
Jun 07

Aurinia Pharmaceuticals holds annual shareholder meeting

Reuters
·
Jun 05

Aurinia presents new analysis of AURORA 1 Phase 3 study of Lupkynis

TIPRANKS
·
Jun 04

Aurinia says Lupkynis cuts renal-related event or death risk 53% in AURORA 1 lupus nephritis analysis

Reuters
·
Jun 04

Lupkynis Associated With a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

THOMSON REUTERS
·
Jun 04

Aurinia Pharmaceuticals up 4% in pre-market after insider transactions

TIPRANKS
·
Jun 03

Aurinia Pharmaceuticals CEO Buys $12.5 Million Worth of Shares

MT Newswires Live
·
Jun 03

Tang Capital Management, Llc Files Early Warning Report Respecting Aurinia Pharmaceuticals Inc.

THOMSON REUTERS
·
Jun 03

Aurinia CEO Kevin Tang reports buying $13.12 million of common shares

Reuters
·
Jun 03

Aurinia issues corporate presentation outlining LUPKYNIS growth strategy, aritinercept development plan

Reuters
·
May 28

Aurinia completes tender offer for Kezar, wins 80% of shares tendered

Reuters
·
May 19